Liability and licensure - authorization as the bottleneck#
Contents
The binding constraint on AI in medicine is not intelligence. It is supply of licensed capacity and reimbursement rules.
Healthcare has never been bottlenecked on knowing what to do; it is bottlenecked on who is permitted to do it and who pays. Adding intelligence to a system constrained on authorization changes less than capability benchmarks imply.
Three layers of the moat#
| Layer | What it is | Who sets it | Speed of change |
|---|---|---|---|
| Licensure | Legal monopoly on acts (diagnose, prescribe, operate) | Legislatures, medical boards | Slow; political |
| Liability | Who pays when the act harms | Courts, statutes, contracts | Slow; then jumps on precedent |
| Insurance | Who will underwrite the residual risk | Underwriters, reinsurers | Continuous; repriced at renewal |
Capability attacks none of these directly. A model that outperforms a median physician still cannot sign a chart, still does not hold a DEA number, and still may be uninsurable as an autonomous actor. → Insurance, Uncertainty 6
The financial moat, restated#
What protects the incumbent professional is often not skill - it is that a malpractice policy exists covering a licensed human and does not yet cover an autonomous system.
That reframes the human moat from a capability claim into a balance-sheet claim. Balance sheets reprice faster than residencies train. A single underwriting shift or a precedent-setting judgment can move the diagnostics employment story more than another generation of model quality.
The reason no carrier writes autonomous clinical risk today is not squeamishness; it is that the risk has the wrong statistical shape for the existing product. Malpractice works as a line of business because physician errors are close to independent: one clinician's bad day does not correlate with another's, so a book of thousands of policies diversifies. A deployed model does not have bad days independently. Every instance shares weights, prompts, and update schedule, so a systematic failure is one event affecting the entire book simultaneously. That converts a diversifiable risk into something closer to catastrophe cover, which requires reinsurance capacity, aggregate limits, and a loss history that does not exist. → Uncertainty 6
This matters for forecasting because it says what actually opens the market. It is not a carrier becoming braver. It is either a vendor with a balance sheet large enough to self-insure and a commercial reason to do it, or a statutory cap that bounds aggregate exposure, or enough deployment history for the tail to be priced. The first is available today to a handful of firms and is the path to watch. A model provider offering indemnity is a stronger signal than any benchmark result, because it means someone with full access to the failure data is willing to bet capital on the failure rate.
Watch C6: a judgment or statute assigning liability for autonomous clinical harm. Provider-side liability collapses the moat in high-volume domains; professional-side liability entrenches it for a decade.
Reimbursement is the other gate#
Even when a tool is accurate and a human will sign, payment rules decide deployment. Codes, prior auth, and site-of-service differentials determine whether the hospital buys the system or shelves the pilot.
AI that reduces cost but also reduces billable RVUs faces a perverse incentive inside fee-for-service. AI that increases throughput under a fixed professional fee is adopted as speed-up. The same model meets opposite fates under different payment regimes - which is why deployment maps to payer policy more than to leaderboard rank.
The clean prediction from this is that capitated and salaried systems adopt clinical AI years ahead of fee-for-service ones, because in a capitated system avoided care is retained revenue and in a fee-for-service system it is forgone revenue. The same is true across borders: national systems with global budgets have the incentive structure that fee-for-service markets lack, and are held back instead by procurement capacity and IT estate rather than by economics. This gives a testable ordering that has nothing to do with which country has the better models, and it predicts that the earliest large-scale clinical deployments look institutionally boring rather than technologically impressive.
The failure mode for the reimbursement claim is that payment codes are not fixed. If a dedicated payment category for autonomous interpretation is established at a price above its delivered cost, the perverse incentive inverts overnight and adoption becomes a margin opportunity rather than a margin threat. Autonomous diabetic retinopathy screening is the existing template for how such a code gets created, and the question is only how far the template generalizes.
Why this is not permanent safety#
Licensure and liability are chosen constraints. They can be rewritten after a crisis, a fiscal crunch, or a rural access collapse. Demography raises the odds of rewrite: a care shortage makes "only physicians may X" politically expensive.
The base case is still slow change through 2030. The tail is a scope-of-practice and liability rewrite in the 18-month window after a salient incident - or after a fiscal event that makes the status quo unaffordable.
Failure modes for the "authorization binds" claim#
- Enterprise indemnification by model providers at scale - risk leaves the hospital balance sheet.
- Safe harbors for AI-assisted standard-of-care when the human follows a certified system.
- Workforce emergency rules (pandemic-style) that expand who may act with model support.
Any of these would make delivery timelines look too pessimistic without the diagnostic models getting smarter.
Coupling to complement erosion#
Licensure and liability capacity are the political rows on the complement list. They do not erode by model quality; they reprice by statute and by underwriting. That makes medicine the cleanest domain in which to watch Uncertainty 7's political channel: a single scope-of-practice expansion or a carrier product for autonomous reads is more informative about the half-life of those rows than another generation of diagnostic benchmarks. The same event is also a C6 trigger. Score it once, revise both pages.
Soft market ≠ real capacity. Early AI riders on malpractice policies written without loss history are competition for premium, not proof the balance-sheet moat fell - same discipline as insurance.
Indemnity from the model provider is the cleanest C6/C6-adjacent signal: someone with failure data is staking capital. Narrow marketing + narrow indemnity is the contest equilibrium; the reverse would reprice the whole medicine stack in one product cycle.
Related: Diagnostics · Insurance · Law · Game 1 · C6 Liability · State capacity
Back to: Medicine hub · Next: Robotics